No description available.

Thesis (M.S.)--University of Missouri-Columbia, 2007. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from title screen of research.pdf file (viewed on March 19, 2008) Includes bibliographical references.

Thesis (M.S.)--University of Missouri-Columbia, 2006. / The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from title screen of research.pdf file (viewed on April 22, 2009) Includes bibliographical references.

Thesis (Ph. D.)--Johns Hopkins University. / Biography. Bibliographical references in foot-notes.

Thesis (Ph. D.)--Johns Hopkins University. / Biography. Bibliographical references in foot-notes.

Thesis (M.S.)--University of Wisconsin--Madison, 1966. / eContent provider-neutral record in process. Description based on print version record. Bibliography: l. 22-26.

Thesis (M.S.)--University of Wisconsin--Madison, 1965. / eContent provider-neutral record in process. Description based on print version record. Bibliography: l. 87-93.

Thesis (M.S.)--State University of New York at Binghamton, Department of Biological Sciences, 2008. / Includes bibliographical references (leaves 45-47)

No description available.

Phenylephrine hydrochloride is a potent adrenergic agent and β-receptor sympathomimetic drug, used in its optically active form (Pandey et al., 2003; Pandey et al., 2006). As an α1-adrenergic receptor agonist, phenylephrine hydrochloride is used ocularly as a decongestant for uveitis and as an agent to dilate the pupil (Lang, 1995). High intraocular doses have been reported to cause tachycardia, hypertension, and headache. These side effects are caused by large amounts of the drop draining into the nasal cavity. Eye drops that contain phenylephrine hydrochloride have proven to have low intra-ocular bioavailability because of a short contact time with the eyes which reduces the amount of drug reaching the site of action. Formulations of phenylephrine hydrochloride eye drops have varying shelf-lives of approximately two to four years. The aim of this study was to formulate and manufacture an eye drop product containing phenylephrine hydrochloride. Important characteristics that were targeted were increased ocular absorption by increasing the viscosity of the product and reduced degradation of phenylephrine hydrochloride. A variety of phenylephrine hydrochloride formulations were manufactured on a laboratory scale using hydroxypropyl methylcellulose (HPMC), glycerol, and sodium carboxy methylcellulose as viscosity modifying agents (VMA). The concentration of phenylephrine hydrochloride was ten percent. Ten millimeters of each formulation was made in triplicate. The quantity in each was evaluated using a previously validated high performance (pressure) liquid chromatography method. Physicochemical properties including pH and colour were also evaluated. Stability was assessed using real time and accelerated stability conditions in accordance with the International Conference on Harmonization (ICH) guidelines. Formulations containing hydroxypropyl methylcellulose (HPMC) as the viscosity modifying agents proved to be stable under all storage conditions when compared with formulations containing other viscosity modifying agents (VMA). However, sodium citrate dihydrate; sodium metabisulphite and EDTA also stabilized the formulations to a certain extent Changes in the appearance and colour of products containing glycerol under accelerated storage conditions were observed. The sodium carboxy methylcellulose (SCMC) containing formulation was found to be physically and chemically stable in two conditions, namely 30 °C/65 percent RH and 25 °C/60 percent RH. The formulations containing hydroxypropyl methylcellulose along with an antioxidant showed to be most stable as it remained aesthetically pleasing did not change colour and did not have a reduction in phenylephrine hydrochloride concentrations. This meant that phenylephrine hydrochloride did not degrade while the viscosity modifying agents remained stable. Rheological tests showed differences in the viscosities of the formulations as glycerol had increased in viscosity over time while HMPC and SCMC displayed relative similarities. The formulations were compared to a marketed eye drop containing polyvinyl alcohol as a VMA. After rheological analysis the formulation containing HPMC displayed better viscosity than the product with polyvinyl alcohol. The preservatives in the formulations were active against the microbial organisms use to challenged them.